Plain-English translation of NCT05327023 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This study is testing a new approach to bone marrow transplant for people with serious blood cancers like leukemia and lymphoma. After you receive your transplant, doctors will give you infusions of immune cells from your donor at carefully planned times and doses. The goal is to boost your body's natural ability to fight any remaining cancer cells while managing side effects.
Even with a bone marrow transplant, high-risk blood cancers often come back, and survival rates remain poor. This medication approach may help prevent relapse by using the donor's immune cells to attack any remaining cancer, while a special type of chemotherapy given during transplant (post-transplantation ) helps prevent the serious side effect of the donor cells attacking your body.
You likely qualify if…
You likely don't qualify if…
You will first undergo a standard bone marrow transplant with special chemotherapy (post-transplantation ). Starting as early as one week after transplant, you will receive infusions of immune cells from your donor on scheduled days. During the first part of the study, doctors will test different doses of these cells to find the safest amount; later participants will receive the dose found to be most effective. You will have frequent clinic visits and blood tests to monitor your health and watch for any side effects.
AI-generated summary from trial data · Aug 3, 2026 · Not medical advice
United States